Purchase this article with an account.
M. Kitahashi, M. Kubota-Taniai, T. Baba, Y. Mitamura, S. Yamamoto; Combined Intravitreal Gas Injection and Intravitreal Bevacizumab for Massive Submacular Hemorrhage Due to Polypoidal Choroidal Vasculopathy. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5611.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine the therapeutic efficacy of combined intravitreal bevacizumab and pneumatic displacement for a massive submacular hemorrhage due to polypoidal choroidal vasculopathy (PCV).
A retrospective study on 5 patients with extensive and thick submacular hemorrhage secondary to PCV. The hemorrhage was displaced pneumatically with intravitreal 0.5 ml SF6, and 1.25 mg of bevacizumab was injected intravitreally. The evaluations included best-corrected visual acuity (BCVA) in logMAR units, optical coherence tomography (OCT)-determined foveal thickness (FT), and fluorescein and indocyanine green angiography before and 3 month after the treatment.
The submacular hemorrhages were displaced inferiorly in all patients. The mean BCVA was improved significantly from 1.21±0.68 to 0.97±0.70(P=0.043).The mean FT decreased significantly from 572±134 µm to 294±194 µm (P=0.043). Leakages from the PCV were resolved in all cases.
Combined therapy with intravitreal gas injection and intravitreal bevacizumab for massive submacular hemorrhage secondary to PCV is relatively successful and well-tolerated. Further comparative studies with larger sample size and longer follow-up are warranted.
This PDF is available to Subscribers Only